CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer

This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.

NCT Number	NCT07704801
Lead Sponsor	Sohag University
Conditions	Metastatic Breast Cancer
Enrollment	300 participants
Start Date	2021-01-01
Primary Completion	2026-11-01 (estimated)
Study Completion	2027-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-15